Skip to main content
. 2020 Jul 30;130:110582. doi: 10.1016/j.biopha.2020.110582

Table 2.

Selection of drugs with highly likely lysosomotropic behaviour and probable antiviral effects.

graphic file with name fx1_lrg.gif

Footnote: Data sources: phospholipidosis [26,31], accumulation in cells calculated according to [30], molecular and phys-chem properties from PubChem [44] and DrugBank [63] (https://www.drugbank.ca/), hepatotoxicity from LiverTox [36], broad spectrum antiviral activity [23] (https://drugvirus.info/), pharmacokinetics and cardiotoxicity ([46,[48], [49], [50], [51], [52],54,55,[57], [58], [59], [60], [61], [62],53,47,56,45]). Green – data indicating lysosomotropism; orange – data indicating cardiotoxicity and hepatotoxicity; blue – data indicating safety; grey – approved drugs; yellow – data indicating broad spectrum antiviral effects; +* - drugs approved only in some countries; n.d. – no data.